FOLH1 and cancer: Six studies (21%) focused only on the identification of margins in primary cancer (tracers used in vivo: 68Ga-PSMA-914; ex vivo: 68Ga-PSMA-11) or local recurrence (in vivo: 99mTc-PSMA-I&S), two (7%) on both prostate and lymph nodes (tracers used ex vivo: 68Ga-PSMA-11 and 18F-BF3-Cy3-ACUPA), and 21 (72%) on identifying tumor-positive lymph nodes during primary or salvage lymph node dissection (LND; tracers used in vivo: 111In-PSMA-617, 111In-PSMA-I&T, 99mTc-PSMA-I&S, and 99mTc-MIP-1404).